VANCOUVER, BC, April 29, 2022 /PRNewswire/ – Atmofizer Technologies Inc. (the “Company” or “Atmofizer“) (CSE: ATMO) (Frankfurt: J3K) (OTCQB: ATMFF) is pleased to announce its financial results for the year ended December 31, 2021. All amounts are expressed in United States dollars unless otherwise noted. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures, see “Non-IFRS Measures” below.
CORORATE DEVELOPMENTS
On February 5, 2021, Vaxxinator Enterprises Inc. (“Vaxxinator“) completed a private placement and issued 4,940,000 common shares at a price of $0.50 per share for gross proceeds of $2,470,000.
On April 15, 2021, Vaxxinator granted 1,800,000 options with an exercise price of $0.50 to the Company’s Chief Executive Officer.
In May 2021 and June 2021, Vaxxinator completed a private placement of 2,478,267 units (the “Units“) at a price of $3.00 per Unit for gross proceeds of $7,434,801. The private placement was completed in different tranches. Each Unit consists of one common share and one half common share purchase warrant. Each whole warrant entitles its holder to purchase one additional common share at an exercise price of $3.50 for a period of two-year from the date of issuance of the warrants, subject to acceleration in the event that the common shares of the Company trade on a recognized Canadian stock exchange and the volume-weighted average price is equal or greater to $7.00 for five consecutive trading days.
On May 17,…
